SCHEMBL27850262

SCHEMBL27850262

COC(=O)c1ccccc1Oc1ccc(N2CCN(Cc3c(O)cccc3Br)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.53
▸ LMNA P02545 2/20 0.53
▸ MAPT P10636 8/20 0.50
▸ MAPK1 P28482 4/20 0.50
▸ KMT2A Q03164 5/20 0.48
▸ CYP2C9 P11712 2/20 0.48
▸ CYP2C19 P33261 2/20 0.48
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ TSHR P16473 2/20 0.43
▸ L3MBTL1 Q9Y468 4/20 0.43
▸ HTT P42858 1/20 0.43
▸ MEN1 O00255 3/20 0.42
▸ TP53 P04637 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ KDM4E B2RXH2 4/20 0.41
▸ PKM P14618 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ DRD2 P14416 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1959118 0.89 ALDH1A1 (0.49) ALDH1A1LMNAMAPTMAPK1KMT2A
SCHEMBL27850269 0.82 KMT2A (0.48) ALDH1A1LMNAMAPTMAPK1KMT2A
SCHEMBL27831709 0.75 CYP2C9 (0.45) ALDH1A1LMNAMAPTKMT2ACYP2C9
SCHEMBL1959654 0.74 BCL2 (0.53) —
SCHEMBL27831767 0.74 KMT2A (0.47) ALDH1A1MAPTKMT2ACYP2C9CYP2C19
SCHEMBL27850282 0.74 KMT2A (0.55) ALDH1A1LMNAMAPTMAPK1KMT2A
SCHEMBL1958252 0.72 BCL2 (0.44) ALDH1A1LMNAMAPTMAPK1KMT2A
Bromobenzene SCHEMBL28102861 0.72 KMT2A (0.48) ALDH1A1LMNAMAPTMAPK1KMT2A
SCHEMBL15897488 0.69 SLC6A3 (0.60) ALDH1A1LMNAMAPTKMT2ATSHR
SCHEMBL26681715 0.69 TSHR (0.55) ALDH1A1LMNAMAPTMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102307872-B BCL-2-selectively apoptosis-inducing agents for the treatment of cancer and immune diseases ABBVIE 公司 2016-06-15 — — CN disclosed
CN-102307872-A BCL-2-selectively apoptosis-inducing agents for the treatment of cancer and immune diseases ABBOTT LAB 2012-01-04 — — CN disclosed
Send feedback